GLP-1 agonist polypeptide compound and salt thereof, synthesis method therefor and use thereof
Summary
USPTO granted patent US12590134B2 to SINOPEP-ALLSINO BIOPHARMACEUTICAL CO., LTD. for a GLP-1 agonist polypeptide compound (SEQ ID NO: 1) used in diabetes and obesity treatment. The patent includes 2 claims covering the compound, salt forms, synthesis method, and therapeutic applications. Filing date was August 17, 2022, under application number 17820251.
What changed
USPTO granted patent US12590134B2 to SINOPEP-ALLSINO BIOPHARMACEUTICAL CO., LTD. covering a GLP-1 agonist polypeptide compound with amino acid sequence H-Xaa1EGTFTSDVSSYLE-Xaa2QAA-Xaa3EFIAWLVRGRG (SEQ ID NO: 1), its salt forms, synthesis methods, and use for treating diabetes (A61P 3/10) and obesity (A61P 3/04). The patent names inventors Chengqing Zhao, Guoqiang Shi, Shunzi Li, and Caidian Wang, and contains 2 claims.\n\nThis is a standard patent grant notification and does not impose compliance obligations. No action is required from other market participants unless they wish to challenge the patent validity or seek licensing arrangements. The patent provides SINOPEP-ALLSINO with exclusive rights to the claimed GLP-1 agonist technology in the United States.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
GLP-1 agonist polypeptide compound and salt thereof, synthesis method therefor and use thereof
Grant US12590134B2 Kind: B2 Mar 31, 2026
Assignee
SINOPEP-ALLSINO BIOPHARMACEUTICAL CO., LTD.
Inventors
Chengqing Zhao, Guoqiang Shi, Shunzi Li, Caidian Wang
Abstract
The disclosure provides a GLP-1 agonist polypeptide compound having an amino acid sequence: H Xaa1EGTFTSDVSSYLE Xaa2QAA Xaa3EFIAWLVRGRG (SEQ ID NO: 1). The C-terminal amino acid of the polypeptide compound is a carboxyl or the carboxyl is amidated. Xaa1 and Xaa2 are the same or different; R1 is: a straight-chain or branched-chain alkyl containing 2-6 carbon atoms, R2 is: H or CH3, X is: O, S or NβCH3, in the formula, R1 and R2 alkyl is optionally substituted by 1-6 halogen atoms.
CPC Classifications
C07K 14/605 C07K 14/001 A61K 38/00 A61P 3/04 A61P 3/10
Filing Date
2022-08-17
Application No.
17820251
Claims
2
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.